IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

Core Insights - IDEAYA Biosciences has entered into a clinical study collaboration and supply agreement with Gilead Sciences to evaluate the efficacy and safety of IDE397, a potential first-in-class MAT2A inhibitor, in combination with Gilead's Trodelvy in MTAP-deletion non-small cell lung cancer (NSCLC) [1][10] - The combination aims to target two distinct and complementary mechanisms related to MTAP-deletion in solid tumors [10] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [8] - The company integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its therapies [8] Clinical Development - IDE397 is a selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), with an estimated prevalence of MTAP-deletion at approximately 15% in NSCLC, translating to around 48,000 cases annually in the U.S. [3][10] - The ongoing Phase 1 trial is expanding to include patients with MTAP-deletion NSCLC, in addition to those with MTAP-deletion urothelial cancer [2][5] Trodelvy Overview - Trodelvy is currently approved in over 50 countries for second-line or later metastatic triple-negative breast cancer (TNBC) and in more than 40 countries for certain pre-treated HR+/HER2-metastatic breast cancer patients [4]